<![CDATA[Five Key Posters From the 2026 SNO/ASCO CNS Metastases Conference]]>

ConferencegabapentinosimertinibPositive

AI Analysis

Summary

Five key posters from the 2026 SNO/ASCO CNS Metastases Conference presented new data linking gabapentin to fewer brain metastases and showing promise for intrathecal therapy and osimertinib, while spotlighting trial barriers in CNS metastasis research.

Outcome Details

Data presented on gabapentin showing association with fewer brain metastases, intrathecal therapy, and osimertinib in CNS metastases; trial barriers highlighted

Importance:4/10

Sentiment:

0.40

CNS metastasesbrain metastasesconference presentationgabapentinosimertinibintrathecal therapySNO/ASCO

Related Companies

$BNN.DE

Read the original article

Published by Cancer Network on August 27, 2026 9:00 PM

Read Original